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Abstract
Hypoxia is a microenvironmental factor that contributes to the invasion, progression and metastasis of tumor cells. Hypoxic
tumor cells often show more resistance to conventional chemoradiotherapy than normoxic tumor cells, suggesting the
requirement of novel antitumor therapies to efficiently eliminate the hypoxic tumor cells. We previously generated a tumor-
specific replication-competent oncolytic adenovirus (OBP-301: Telomelysin), in which the human telomerase reverse
transcriptase (hTERT) promoter drives viral E1 expression. Since the promoter activity of the hTERT gene has been shown to
be upregulated by hypoxia, we hypothesized that, under hypoxic conditions, the antitumor effect of OBP-301 with the
hTERT promoter would be more efficient than that of the wild-type adenovirus 5 (Ad5). In this study, we investigated the
antitumor effects of OBP-301 and Ad5 against human cancer cells under a normoxic (20% oxygen) or a hypoxic (1% oxygen)
condition. Hypoxic condition induced nuclear accumulation of the hypoxia-inducible factor-1a and upregulation of hTERT
promoter activity in human cancer cells. The cytopathic activity of OBP-301 was significantly higher than that of Ad5 under
hypoxic condition. Consistent with their cytopathic activity, the replication of OBP-301 was significantly higher than that of
Ad5 under the hypoxic condition. OBP-301-mediated E1A was expressed within hypoxic areas of human xenograft tumors
in mice. These results suggest that the cytopathic activity of OBP-301 against hypoxic tumor cells is mediated through
hypoxia-mediated activation of the hTERT promoter. Regulation of oncolytic adenoviruses by the hTERT promoter is a
promising antitumor strategy, not only for induction of tumor-specific oncolysis, but also for efficient elimination of hypoxic
tumor cells.
Citation: Hashimoto Y, Tazawa H, Teraishi F, Kojima T, Watanabe Y, et al. (2012) The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus
under a Hypoxic Microenvironment. PLoS ONE 7(6): e39292. doi:10.1371/journal.pone.0039292
Editor: Ilya Ulasov, University of Chicago, United States of America
Received November 10, 2011; Accepted May 18, 2012; Published June 15, 2012
Copyright:  2012 Hashimoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to TF and FT, http://www.
mext.go.jp/english/) and by grants from the Ministry of Health, Labour and Welfare of Japan (to TF, http://www.mhlw.go.jp/english/). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: YU is an employee of Oncolys BioPharma, Inc., the manufacturer of OBP-301. TF is a consultant of Oncolys BioPharma, Inc. This does not
alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: toshi_f@md.okayama-u.ac.jp
Introduction
Solid tumor tissues often contain hypoxic regions, in which the
supply of oxygen and nutrition is reduced because of an immature
vascular network, and in which there is rapid tumor progression
[1]. Hypoxia is a critical microenvironmental factor that
contributes to tumor angiogenesis, invasion, progression and
metastasis [1,2]. Indeed, hypoxic conditions have been shown to
be associated with cancer progression and poor prognosis [3–5].
Furthermore, recent accumulated evidence suggests that hypoxia
induces cancer progression-related characteristics such as epithe-
lial-mesenchymal transition (EMT) [6,7] and stemness properties
[8–11] of tumor cells. Acquisition of such properties by tumor cells
within hypoxic areas of tumor tissues would greatly contribute to
tumor progression and recurrence.
Hypoxic tumor cells are known to be highly resistant to
conventional chemoradiotherapy, leading to poor prognosis
[5,12]. To improve clinical outcome, novel antitumor agents that
efficiently eradicate tumor cells under hypoxic conditions as well as
under normoxic conditions are required. Oncolytic virotherapy
has emerged as a promising novel antitumor therapy [13]. We
previously generated a telomerase-specific replication-competent
oncolytic adenovirus (OBP-301: Telomelysin), in which the
human telomerase reverse transcriptase (hTERT) promoter
element drives E1 gene expression. OBP-301 efficiently kills
human cancer cells but not normal human somatic cells [14].
hTERT is a catalytic subunit of human telomerase and is highly
expressed in tumor cells, but not in normal cells. hTERT
expression closely correlates with telomerase activity [15–17].
Tumor-specific antitumor activity of OBP-301 against various
types of human cancer cells with high telomerase activity has been
demonstrated in both in vitro and in vivo settings [14,18,19].
Furthermore, the feasibility of OBP-301 for clinical use has been
demonstrated in a recently completed phase I clinical trial in the
USA of OBP-301 in patients with advanced solid tumors [20].
However, whether OBP-301 has an antitumor effect against
hypoxic tumor cells remains unclear.
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Hypoxia-inducible factor 1 (HIF-1) is a master transcription
factor that is activated by hypoxia [1]. HIF-1 consists of a and b
subunits and HIF-1a expression is tightly regulated by oxygen
concentration. The HIF-1a protein is stabilized under hypoxic
conditions, whereas it is immediately degraded under normoxic
conditions. HIF-1a induces the expression of many down-stream
target genes that are associated with cellular metabolism,
proliferation, survival, apoptosis, neovascularization and migration
[4]. The expression of many target genes is activated by HIF-1
through binding to a cis-acting hypoxia response element (HRE)
located at their enhancer or promoter regions [4,21,22]. The
hTERT gene is also a HIF-1-target gene. Two HREs that are
present in the hTERT gene promoter are involved in hypoxia-
mediated hTERT gene upregulation [23–25]. In contrast, it has
also been shown that hypoxic conditions impair the replication of
wild-type adenovirus in tumor cells [26,27]. Based on these
findings, we hypothesized that the cytopathic activity of OBP-301
that is regulated by the hTERT gene promoter would be much
stronger against hypoxic tumor cells than that of wild-type
adenovirus due to hypoxia-induced enhancement of OBP-301
virus replication.
In the present study, we evaluated whether hypoxic conditions
affect the expression levels of hTERT and the coxsackie and
adenovirus receptor (CAR) in human cancer cells. We next
assessed the antitumor effects of OBP-301 and Ad5 against human
cancer cells under normoxic or hypoxic conditions. We further
evaluated the replication of OBP-301 within hypoxic areas of
human xenograft tumors.
Results
Maintenance of human cancer cells under hypoxic
conditions
A hypoxia chamber filled with a gas mixture of 1% O2, 5%
CO2 and 94% N2 was used to maintain human cancer cells under
hypoxic conditions. Human cancer cells were also maintained
under normoxic conditions, consisting of 20% O2 and 5% CO2.
To first confirm that the tumor cells were efficiently exposed to
hypoxia in the chamber, the expression of HIF-1a, which is the
main transcription factor induced by hypoxia [1], was evaluated
using Western blot analysis. Consistent with HIF-1a induction by
exposure to cobalt chloride (CoCl2), HIF-1a expression was
strongly induced in human cancer cells (HT29, DLD-1, H1299)
maintained in the hypoxia chamber (Fig. 1A). However, no, or
slight, HIF-1a expression was detected under normoxic condi-
tions. Moreover, using immunocytochemistry, we further con-
firmed that HIF-1a was expressed and accumulated in the nuclei
of human cancer cells under hypoxic conditions, but not under
normoxic conditions (Fig. 1B). These results indicate that human
cancer cells are maintained under hypoxic conditions in the
hypoxia chamber.
Expression of hTERT and the adenovirus receptor in
human cancer cells under hypoxic conditions
OBP-301 contains the hTERT gene promoter, which allows
tumor-specific regulation of the gene expression of E1A and E1B
that are required for viral replication [14]. The activity of the
hTERT gene promoter in human cancer cells has been shown to
be upregulated under hypoxic conditions [23–25], suggesting that
hypoxia would enhance OBP-301 replication through upregula-
tion of hTERT gene promoter activity. To evaluate the effect of
hypoxic conditions on the activity of the hTERT gene promoter in
tumor cells, we first investigated the expression level of hTERT
mRNA in human tumor cells under normoxic or hypoxic
conditions by quantitative real-time RT-PCR analysis. The
expression of hTERT mRNA was increased in all tumor cells
under the hypoxic condition by 1.3 to 4.3-fold compared to the
normoxic condition (Fig. 2A). Despite evident inductions of HIF-
1a by hypoxia, the increases were not statistically significant in
HT29 and DLD-1 cells. Because it is known that hTERT
expression is regulated not only transcriptionally but also post-
transcriptionally by alternative splicing [25], we further examined
the effects of hypoxia on activity of exogenous hTERT gene
promoter using luciferase reporter assay. Hypoxia activated the
hTERT gene promoter by at least 3-fold compared to the hTERT
gene promoter activity under normoxia (Fig. 2B). To further
confirm hypoxia-induced hTERT promoter activation, we used
chemical inhibitor of HIF-1a. The protein expression of HIF-1a
and the activity of hTERT gene promoter were significantly
decreased in HT29 and H1299 cells treated with 30 mM HIF-1a
inhibitor LW6 and cultured in hypoxic condition (Fig. S1 and
Fig. 2C). Moreover, we confirmed that hTERT protein was
expressed and accumulated in nuclei of human cancer cells under
hypoxic conditions by immunofluorescence staining (Fig. 2D).
These results suggest that the hTERT gene promoter in OBP-301
is more strongly activated under the hypoxic condition than under
the normoxic condition.
The infection efficiency of Ad5-based viral vectors depends
mainly on the expression of the adenoviral receptor CAR in target
cells [28]. Therefore, to evaluate whether hypoxic conditions affect
the expression of CAR in tumor cells, we examined the expression
level of CAR in all tumor cells under normoxic or hypoxic
conditions by flow cytometry. CAR expression was clearly
detected in all tumor cells tested: the percentage of CAR-positive
cells was 99.5%, 99.3% and 98.8% for HT29, DLD-1 and H1299
cells, respectively (Fig. 2E). All tumor cell lines showed similar
expression levels of CAR under normoxic and hypoxic conditions.
These results indicate that tumor cells show high CAR expression
under hypoxic conditions as well as under normoxic conditions.
Antitumor activities of OBP-301 and Ad5 against hypoxic
tumor cells
To explore the potential antitumor activities of the telomerase-
dependent oncolytic adenovirus OBP-301 against normoxic and
hypoxic tumor cells, we investigated the cytopathic activities of
OBP-301 and Ad5 against tumor cells under normoxic or hypoxic
conditions. Under normoxic conditions, the cytopathic activities of
OBP-301 and Ad5 against HT29 and DLD-1 cells were very
similar. The cytopathic activity of OBP-301 against H1299 cells
was significantly higher than that of Ad5 at a low dose of infection,
whereas it was similar to that of Ad5 at a high dose of infection
(Fig. 3A). In contrast, under hypoxic conditions, the cytopathic
activity of OBP-301 against all tumor cells was significantly higher
than that of Ad5, especially at a high dose of infection (Fig. 3B). To
further evaluate the antitumor activities of OBP-301 and Ad5
against hypoxic tumor cells, the 50% inhibiting dose (ID50) values
of OBP-301 and Ad5 under a hypoxic or a normoxic condition
were calculated. The calculated ID50 values indicated that the
cytopathic activity of OBP-301 against all tumor cells under
hypoxic conditions was higher than that of Ad5, although the
cytopathic activities of OBP-301 and Ad5 were very similar under
normoxic conditions (Table 1). These results suggest that the
cytopathic activity of OBP-301 against hypoxic tumor cells is more
efficient than that of Ad5.
Oncolytic Virotherapy under Hypoxia
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Increased replication of OBP-301 compared to that of
Ad5 under hypoxic conditions
We next examined the ability of OBP-301 and Ad5 to replicate
in HT29, DLD-1 and H1299 cells, which showed almost similar
sensitivity to OBP-301 and Ad5 under normoxic conditions but
different sensitivity under hypoxic conditions (Fig. 3). The
replication ability of OBP-301 and Ad5 was quantified by
measuring viral E1A DNA in tumor cells infected with OBP-301
or Ad5 using quantitative real-time PCR analysis. Under
normoxic conditions, the amount of virus production was very
similar in tumor cells after infection with OBP-301 or Ad5 (Fig. 4).
In contrast, under hypoxic conditions, viral production was
significantly increased in OBP-301-infected tumor cells compared
to Ad5-infected cells (Fig. 4). These results suggest that the
replication of OBP-301 within hypoxic tumor cells is more
efficient than that of Ad5.
OBP-301-mediated E1A expression in the hypoxic regions
of xenograft tumor tissues
To investigate whether OBP-301 actually replicates in the
hypoxic regions of tumor tissues, we examined HT29 and DLD-1
xenograft tumors after intratumoral injection of OBP-301. OBP-
301-mediated E1A protein expression was assessed in HT29 and
DLD-1 xenograft tumors by immunohistochemistry. Hypoxic
areas in tumor tissues were detected by immunohistochemical
analysis of the exogenous hypoxic marker, pimonidazole hydro-
chloride. OBP-301-mediated E1A was expressed in the normoxic
regions (Fig. 5Aa and 5Ba) and the regions that were confirmed to
be hypoxic by detection of pimonidazole expression (Fig. 5Ab and
5Bb). Moreover, the quantitative image analysis of immunohisto-
chemical stains showed that the E1A-positive areas were almost
equal in pimonidazole-negative and pimonidazole-positive regions
(Fig. 5C and 5D). These results suggest that OBP-301 replicates in
hypoxic tumor cells within the hypoxic areas of tumor tissues.
Discussion
Hypoxic microenvironments contribute to tumor invasion,
progression, metastasis and resistance to conventional antitumor
therapy, such as chemotherapy and radiotherapy, leading to poor
prognosis [1–5]. The development of novel antitumor therapies
that efficiently eliminate hypoxic tumor cells is an urgent issue for
improvement of the clinical outcome of cancer patients. Although
adenovirus-based oncolytic virotherapy has recently emerged as a
promising antitumor therapy, a hypoxic microenvironment has
been shown to reduce the replication of wild-type adenovirus in
target tumor cells [26,27]. Therefore, efficient replication of an
oncolytic adenovirus under hypoxic conditions is a critical factor
for the eradication of hypoxic tumor cells. In this study, our goal
was to assess whether the telomerase-specific oncolytic adenovirus
OBP-301 that is regulated by the hTERT gene promoter shows
cytopathic activity against human tumor cells under hypoxic
conditions. We demonstrated that the cytopathic activity of OBP-
301 against hypoxic tumor cells was much stronger than that of
wild-type adenovirus (Fig. 3 and Table 1). Hypoxia-mediated
Figure 1. Increased HIF-1a expression in human cancer cells under hypoxic conditions. A, Western blot analysis of HIF-1a protein
expression in human cancer cells (HT29, DLD-1 and H1299) under normoxic (Nx) or hypoxic (Hx) conditions. Cells were maintained under a normoxic
(20% O2) or a hypoxic (1% O2) condition for 18 h. HT29 cells were also exposed to CoCl2 as a positive control. Cell lysates were subjected to Western
blot analysis using an anti- HIF-1a antibody. b-actin was assayed as a loading control. B, Subcellular localization of HIF-1a expression in human cancer
cells under normoxia or hypoxia was assessed using immunofluorescent staining. Cells cultured under a normoxic or a hypoxic condition for 18 h
were stained with anti-HIF-1a antibody (red). Nuclei were counterstained with DAPI (blue). Scale bars = 50 mm.
doi:10.1371/journal.pone.0039292.g001
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activation of the hTERT gene promoter was involved in the
enhancement of virus replication in hypoxic tumor cells (Fig. 2 and
4). These results suggest that the hTERT gene promoter is useful
for regulation of the replication of oncolytic adenoviruses in tumor
cells in a hypoxic microenvironment.
The replication of OBP-301 depends on the activity of the
hTERT gene promoter, which contains two HREs and is activated
by HIF-1a under hypoxic conditions [23–25]. Hypoxic conditions
that induced nuclear accumulation of HIF-1a (Fig. 1) upregulated
hTERT gene promoter activity in human cancer cells (Fig. 2B and
2C). Consistent with this hTERT gene promoter activation, OBP-
301 replication was significantly higher than that of Ad5 with the
endogenous E1 promoter (Fig. 4). These findings suggest that
hypoxia enhances OBP-301 virus replication through HIF-1a-
mediated activation of the hTERT gene promoter.
Recently, oncolytic virotherapy has garnered interest as
potential therapeutic strategy for hypoxic tumors [29]. A
hypoxia-responsive promoter that is upregulated by HIF-1 has
been used for the tumor-specific replication of an oncolytic
adenovirus [30–32]. Although an oncolytic adenovirus that is
regulated by a hypoxia-responsive promoter will also be effective
against hypoxic tumor cells following HIF-1 activation, non-
hypoxic tumor cells in which HIF-1 is not activated may be less
sensitive to these viruses. In contrast, the hTERT gene promoter-
regulated oncolytic adenovirus OBP-301 would be effective
Figure 2. Effect of hypoxia on hTERT and CAR expression in human cancer cells. A, hTERT mRNA expression was assessed in human cancer
cells that were maintained under normoxia (Nx) or hypoxia (Hx) for 18 h, using quantitative real-time RT- PCR analysis. The levels of hTERTmRNA were
plotted as fold induction relative to the values of hTERT mRNA in HT29 cells incubated under normoxia, which was set at 1.0. Data are shown as mean
values 6 SD of triplicate experiments. Statistical significance (*) was determined as P,0.05 (Student’s t test). B and C, hTERT gene promoter activity
was assessed in human cancer cells that were transfected with the hTERT reporter vector (pGL3-hTERT) and then cultured under normoxia or hypoxia
for 24 h, using luciferase reporter assay. The GFP expression vector (pCMV-EGFP) was used as a reporter for transfection efficiency, and the activities
of hTERT promoter were determined as ratio of luciferase activity to GFP expression. Data are shown as mean values 6 SD of triplicate experiments.
Statistical significance (*) was determined as P,0.05 (Student’s t test). C, HT29 and H1299 cells were treated with 30 mM HIF-1a inhibitor or DMSO
solvent control in hypoxic condition. The levels of luminescence were plotted as fold induction relative to the values of luminescence in cancer cells
incubated under normoxia, which were set at 1.0. D, Subcellular localization of hTERT protein expression in human cancer cells under normoxia or
hypoxia was assessed using immunofluorescent staining. Cells cultured under a normoxic or hypoxic condition for 48 h were stained with anti-hTERT
antibody (green). Nuclei were counterstained with DAPI (blue). Scale bars = 50 mm. E, Flow cytometric analysis of CAR expression in human cancer
cells maintained under normoxia (green) or hypoxia (red) for 18 h. Cells were incubated with a mouse anti-CAR antibody followed by FITC-labeled
rabbit anti-mouse IgG. An isotype-matched normal mouse IgG was used as a control (black).
doi:10.1371/journal.pone.0039292.g002
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against both hypoxic and normoxic tumor cells through hTERT
activation.
The infection efficacy of Ad5-based oncolytic adenoviruses has
been suggested to depend mainly on the expression level of CAR
on the target cell surface [28]. Hypoxia has been shown to
downregulate CAR expression in tumor cells in a HIF-1a
dependent manner [33]. However, in the present study, high
CAR expression was maintained in all of the human cancer cells
tested, even under hypoxic conditions (Fig. 2E). These results are
consistent with a previous report [27], which demonstrated that
hypoxia has no influence on adenoviral infectivity of target cancer
cells. The expression levels of integrin avb3 and avb5 are also
involved in the infection efficacy of adenoviruses [34]. Previous
reports have shown that hypoxia upregulates the expression levels
of integrin avb3 and avb5 in tumor cells [35,36]. These results
suggest that hypoxic conditions would mainly suppress the
replication of an adenovirus rather than the infection efficiency
of the adenovirus.
Tumor tissues frequently contain hypoxic areas due to an
immature vascular network. Various exogenous and endogenous
hypoxia-related proteins have recently been developed as markers
for identification of hypoxic regions of tumor tissues. Increased
HIF-1 expression is a useful endogenous marker of hypoxic areas
close to blood vessels. Expression of the exogenous hypoxia
marker, Pimonidazole, is as effective a marker as HIF-1 for the
detection of severely hypoxic regions [37]. In this study, OBP-301-
mediated E1A expression was detected in pimonidazole-positive
regions as well as normoxic regions (Fig. 5). These results indicate
that the telomerase-specific oncolytic adenovirus OBP-301 could
Figure 3. Cytopathic effect of OBP-301 and wild-type adenovirus serotype 5 (Ad5) under normoxic or hypoxic conditions. Cells were
infected with OBP-301 (solid bars) or wild-type Ad5 (diagonal bars) at the indicated MOIs under normoxic (A) or hypoxic (B) conditions for 3 days. Cell
viability was determined using an XTT assay. Cell viability was calculated relative to that of mock-treated cells, whose viability was set at 100%.
Cytopathic activity was further calculated using the following formula; Cytopathic activity (%) = 100 (%) – cell viability (%). The results shown are the
mean values 6 SD of quadruplicate experiments. Statistical significance (*) was determined as P,0.05 (Student’s t test).
doi:10.1371/journal.pone.0039292.g003
Oncolytic Virotherapy under Hypoxia
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39292
infect and replicate in tumor cells under a hypoxic microenviron-
ment including in tumor cells in which HIF-1 was active.
Recent advances in our knowledge of tumor microenvironments
have provided evidence that hypoxic tumor cells contribute to
cancer progression. For example, hypoxia activates the metastatic
potential of tumor cells by inducing EMT [6,7] and facilitates the
maintenance of cancer stem cells [8–11]. Therefore, the complete
elimination of hypoxic tumor cells with metastatic and stemness
properties is important for improvement of the clinical outcome of
cancer patients. Recent reports have suggested that tumor cells
undergoing EMT show reduced CAR expression [38,39],
suggesting that tumor cells undergoing EMT are less sensitive to
oncolytic adenovirus infection. Further study to investigate the
cytopathic effect of OBP-301 in tumor cells undergoing EMT is
warranted. In contrast, recent reports have shown that an
oncolytic adenovirus induces oncolytic cell death in cancer stem
cells [40–43]. Cancer stem cells have recently been shown to have
increased hTERT expression compared to non-cancer stem cells
[44,45]. Consistent with this high hTERT expression in cancer
stem cells, Hemminki et al. has suggested that an oncolytic
adenovirus that is regulated by specific promoters for hTERT,
cyclooxygenase-2 or multidrug resistance, shows efficient cyto-
pathic activity against human breast cancer stem cells [46]. Thus,
the hTERT promoter-regulated oncolytic adenovirus OBP-301
may have the potential to eliminate highly progressive tumor cells
in a hypoxic microenvironment, thereby contributing to the
improvement of its therapeutic benefit against malignant tumors.
In conclusion, we have clearly demonstrated that the antitumor
effect of the telomerase-specific oncolytic adenovirus OBP-301
against tumor cells in a hypoxic microenvironment is much
stronger than that of a wild-type adenovirus. Regulation of virus
replication by the hTERT gene promoter would be an effective
antitumor strategy that would enhance the cytopathic activity of
an oncolytic adenovirus against hypoxic tumor cells.
Materials and Methods
Cell lines
The human colorectal cancer (DLD-1 and HT29) and non-
small cell lung cancer (H1299) cell lines were purchased from the
American Type Culture Collection (ATCC) (Manassas, VA,
USA). Although cell lines were not authenticated by the authors,
cells were immediately expanded after receipt and stored in liquid
N2. Cells were not cultured for more than 5 months following
resuscitation. DLD-1 and H1299 cells were propagated as
monolayer cultures in RPMI-1640 medium. HT29 was grown in
McCoy’s 5A medium. The transformed embryonic kidney cell line
293 obtained from the ATCC was maintained in Dulbecco’s
Table 1. Comparison of the ID50 values of OBP-301 and Ad5
against human cancer cells under normoxia and hypoxia.
Cell lines Viruses ID50 value
a) (MOI)
Ratiob) (Hx/
Nx)
Normoxia Hypoxia
HT29 OBP-301 20.261.5 51.767.3 2.5
Ad5 25.664.3 212.8652.0 9.4
DLD-1 OBP-301 8.262.7 26.3610.3 3.0
Ad5 6.661.9 2359.66440.7 597.1
H1299 OBP-301 8.161.2 5.360.9 0.8
Ad5 15.160.9 18.867.8 1.3
a)The ID50 values of OBP-301 and Ad5 were calculated from the data of the XTT
assay at day 3 after infection. Data are shown as the mean values 6 SE of
triplicate experiments.
b)The ratio was calculated by division of the ID50 value under hypoxia (Hx) by
the ID50 value under normoxia (Nx).
doi:10.1371/journal.pone.0039292.t001
Figure 4. Quantification of viral DNA replication in human cancer cells under normoxia or hypoxia. The indicated human cancer cells
were infected with OBP-301 or Ad5 at an MOI of 50 PFU/cell for 1 h, and were further incubated under normoxic (Nx) or hypoxic (Hx) conditions for
48 h. After incubation, cells were harvested and counted. E1A copy number in the cells at 48 h after incubation under normoxia or hypoxia was
analyzed by quantitative PCR analysis. The amount of virus production was defined as the value of the E1A copy number relative to the number of
cancer cells. Data are shown as the mean values6 SE of triplicate experiments. Statistical significance (*) was determined as P,0.05 (Student’s t test).
doi:10.1371/journal.pone.0039292.g004
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modified Eagle’s medium containing high glucose (4.5 g/L). All
media were supplemented with 10% heat-inactivated fetal calf
serum, 100 units/ml penicillin G and 100 mg/ml streptomycin. To
maintain human cancer cells under hypoxic conditions, the cells
were incubated in a hypoxic chamber (Modular Incubator
Chamber; Billups-Rothenberg, Del Mar, CA, USA) filled with a
gas mixture of 1% O2, 5% CO2 and N2. The cells were also
incubated under normoxic conditions at 37uC in a humidified
atmosphere with 5% CO2 and 20% O2. HIF-1a inhibitor LW6
was purchased from Calbiochem (San Diego, CA, USA) and used
at the concentration of 30 mM.
Recombinant adenoviruses
The recombinant replication-selective, tumor-specific adenovi-
rus OBP-301 (Telomelysin), in which elements within the hTERT
gene promoter drive the expression of E1A and E1B genes linked
with an internal ribosome entry site, was previously constructed
and characterized [14]. The wild-type Ad5 was used as a control
vector. OBP-301 and Ad5 were generated in 293 cells and purified
by cesium chloride step-gradient ultracentrifugation. Their infec-
tious titers were determined by a plaque-forming assay using 293
cells. The ratios of viral particle/plaque-forming unit of OBP-301
and Ad5 are 26 and 27, respectively. Viruses were stored at
280uC.
Western blot analysis
Cells were maintained under a hypoxic or a normoxic condition
for 18 h or 24 h. Whole cell lysates were then prepared in a lysis
buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10%
glycerol, 0.5% NP40) containing a protease inhibitor mixture
(Complete Mini; Roche, Indianapolis, IN, USA). Lysates were
electrophoresed on 4%–7% SDS polyacrylamide gels and proteins
were transferred to polyvinylidene difluoride membranes (Hy-
bond-P; GE Healthcare, Buckinghamshire, UK). The primary
antibodies used for Western blotting were: mouse anti-HIF-1a
monoclonal antibody (mAb) (BD Biosciences, San Diego, CA,
USA) and mouse anti-b-actin mAb (Sigma, St. Louis, MO, USA).
Horseradish peroxidase-conjugated antibody against mouse IgG
Figure 5. E1A expression in hypoxic areas of human xenograft tumors intratumorally injected with OBP-301. HT29 (A and C) and DLD-
1 (B and D) tumor cells (56106cells/mouse) were injected subcutaneously into the flank of athymic nude mice. Two weeks after inoculation, OBP-301
(16108 PFU/tumor) was injected into the tumor for three cycles every 2 days. One day after final administration of OBP-301, the mice were
intraperitoneally injected with the hypoxia marker pimonidazole hydrochloride (120 mg/kg). Thirty minutes after injection of pimonidazole
hydrochloride, the mice were sacrificed and the tumors were harvested. Paraffin-embedded sections of HT29 and DLD-1 tumors were stained with
hematoxylin and eosin (H&E). Tumor sections were also immunostained with an anti-pimonidazole antibody and an anti-adenovirus E1A antibody. A
and B, Middle (a) and right (b) panels are higher magnifications of the boxed regions in the left panels. Original magnification:64 (left panels),640
(middle and right panels). Scale bars = 100 mm. C and D, Quantitative analysis of the E1A-positive areas in the normoxic and hypoxic regions of
human xenografts tumor tissues. Data are shown as mean values 6 SD of quadruplicate experiments.
doi:10.1371/journal.pone.0039292.g005
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(GE Healthcare) was used as the secondary antibody. Immuno-
reactive bands on the blots were visualized using enhanced
chemiluminescence substrates (ECL Plus; GE Healthcare).
Immunofluorescence staining
Cells grown in chamber slides were washed twice with ice-cold
PBS, and then fixed with cold 4% paraformaldehyde in PBS for
15 min on ice. The cells were permeabilized by incubation with
0.2% Triton X-100 in PBS for 5 min on ice and then blocked with
3% bovine serum albumin in PBS for 30 min at room
temperature. The slides were subsequently incubated with mouse
anti-HIF-1a mAb (BD Biosciences) or mouse anti-hTERT mAb
(KYOWA Medex, Tokyo, JP) for 1 h at room temperature. After
two washes with PBS, the slides were incubated with Alexa Fluor
488- or Alexa Fluor 568-labeled goat anti-mouse IgG antibody
(Invitrogen, Carlsbad, CA, USA) for 1 h. The slides were further
stained with 10 mg/ml 49,6-diamidino-2-phenylindole (DAPI),
mounted using Fluorescence Mounting Medium (Dako, Glostrup,
Denmark), and then photographed using a fluorescence micro-
scope (IX71; Olympus, Tokyo, Japan).
Quantitative real-time RT-PCR analysis
Total RNA was extracted from cancer cells maintained under
hypoxic or normoxic conditions for 18 h using the RNA-Bee
regent (Tel-test; Friendswood, TX, USA). The hTERT mRNA
copy number was determined by quantitative real-time reverse
transcription-polymerase chain reaction (RT-PCR) using a Light-
Cycler instrument and a LightCycler TeloTAGGG hTERT
Quantification Kit (Roche Diagnostics, Bagel, Switzerland). Data
analysis was performed using LightCycler Software. The expres-
sion of hTERT mRNA was defined from the threshold cycle (Ct),
and relative expression levels were calculated after normalization
with reference to the expression of porphobilinogen deaminase
(PBGD).
Transfection and luciferase reporter assay
Cells were seeded on 6-well plates at a density of 46105 cells/
well and incubated overnight. Each cell line was transfected with
3 mg of hTERT reporter plasmid (pGL3-hTERT) and 3 mg of
GFP expression vector (pCMV-EGFP) as a reporter for transfec-
tion efficiency, using Lipofectamin LTX (Invitrogen) following the
manufacturer’s recommendations. Cells were then incubated
under normoxic or hypoxic conditions. After 24 h incubation,
luciferase activity was determined using a Bright-Glo reagent
(Promega Corporation, Madison, WI, USA). Results presented are
the ratios of luciferase activity to GFP fluorescent intensity and the
means of three independent experiments.
Flow cytometric analysis
The cells that were maintained under hypoxic or normoxic
conditions for 18 h were labeled with a mouse anti-CAR mAb
(Upstate Biotechnology, Lake Placid, NY, USA) for 30 min at
4uC. An isotype-matched normal mouse IgG1 (Serotec, Oxford-
shire, UK) was used as a negative control. The cells were then
incubated with a fluorescein isothiocyanate (FITC)-conjugated
rabbit anti-mouse IgG second antibody (Zymed Laboratories, San
Francisco, CA, USA) and were analyzed using flow cytometry
(FACSCalibur; Becton Dickinson, Mountain View, CA, USA).
Cell viability assay
Cells were seeded on 96-well plates at a density of 16104 cells/
well 20 h before viral infection. All cell lines were infected with
OBP-301 or wild-type Ad5 at multiplicity of infections (MOI) of 0,
1, 5, 10, 50 or using 100 plaque-forming units (PFU)/cell. The
cells were then incubated under normoxic or hypoxic conditions
for 3 days. Cell viability was determined using a Cell Proliferation
Kit II (Roche Diagnostics) that was based on a sodium 39-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)
benzene sulfonic acid hydrate (XTT) assay according to the
manufacturer’s protocol. The cytotoxic activity and the ID50 value
of each virus was calculated using cell viability data. Each
experiment was performed in quadruplicate during the same day
and repeated at least three times.
In vitro virus replication assay
Cells were seeded on 6-well plates at a density of 36105 cells/
well 20 h before viral infection and were infected with OBP-301 or
wild-type Ad5 at an MOI of 50 for 1 h. Following removal of the
viral inocula, the cells were further maintained under hypoxic or
normoxic conditions and were then harvested at 48 h after virus
infection. After cell counting, DNA was purified using the QIAmp
DNA mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. E1A copy numbers were determined by
quantitative real-time PCR using the StepOnePlus Real Time
PCR System (Applied Biosystems, Carlsbad, CA, USA) and
TaqMan Gene Expression Assays (Applied Biosystems). The
sequences of the specific primers and probe used in this
experiment were: E1A primers, 59-CCT GAG ACG CCC GAC
ATC-39 and 59-GGA CCG GAG TCA CAG CTA TCC-39; E1A
probe, 59-FAM-CTG TGT CTA GAG AAT GC-MGB-39. Data
analysis was carried out using StepOne Software (Applied
Biosystems).
In vivo human xenograft tumor models
Animal experimental protocols were approved by the Ethics
Review Committee for Animal Experimentation of Okayama
University School of Medicine (Approval ID: OKU-2009051).
The HT29 and DLD-1 cells (56106 cells per site) were inoculated
subcutaneously into the flank of 5- to 6-week-old female BALB/c
nu/nu mice (Japan SLC, Shizuoka, Japan). When the tumor size
reached approximately 10 mm in diameter, OBP-301 was injected
into the tumors at a dose of 16108 PFU/tumor every 2 days for
three cycles. To detect hypoxic areas within tumor tissues,
pimonidazole hydrochloride (Hypoxyprobe -1; Hypoxyprobe
Inc., Burlington, MA, USA) was injected intraperitoneally at a
dose of 120 mg/kg body weight 24 h after the final treatment. The
mice were then sacrificed and the tumors were harvested 30 min
after pimonidazole injection. Four mice were used for each group.
Immunohistochemistry
Tumors were fixed in 10% neutralized formalin and embedded
in paraffin blocks. Sections (4 mm) were prepared for hematoxy-
lin/eosin staining and also for immunohistochemical examination.
After deparaffinization and rehydration, antigen retrieval was
performed by microwave irradiation in 10 mM citrate buffer
(pH 6.0). After quenching of endogenous tissue peroxidase, tissue
sections were incubated with mouse anti-adenovirus type 5 E1A
mAb (BD Biosciences) and mouse anti-Hypoxyprobe-1 mAb
(Hypoxyprobe Inc.). The sections were then incubated using the
Histofine Mouse Stain Kit (Nichirei Biosciences, Tokyo, Japan).
Immunoreactive signals were visualized by using 3,39-diamino-
benzidine tetrahydrochloride solution, and the nuclei were
counterstained with hematoxylin. Signals were viewed under a
microscope (BX50; Olympus). The percentage of the positive area
in each field was analyzed using Image J software (version 1.45).
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Statistical analysis
Determination of significant differences among groups was
assessed by using the Student’s t test. P,0.05 was considered
significant.
Supporting Information
Figure S1 Suppression of HIF-1a expression in human
cancer cells under hypoxic conditions by HIF-1 inhibi-
tor. A, Western blot analysis of HIF-1a protein expression in
human cancer cells (HT29 and H1299) under normoxic or
hypoxic conditions. Cells were treated with 30 mM HIF-1a
inhibitor or DMSO solvent control under hypoxic condition for
24 h. Cell lysates were subjected to Western blot analysis using an
anti- HIF-1a antibody. b-actin was assayed as a loading control.
B, Subcellular localization of HIF-1a expression in human cancer
cells treated with 30 mM HIF-1a inhibitor or DMSO solvent
control under hypoxia was assessed using immunofluorescent
staining. Cells cultured under a hypoxic condition for 24 h were
stained with anti-HIF-1a antibody (red). Nuclei were counter-
stained with DAPI (blue). Scale bars = 50 mm.
(TIF)
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